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1. Introduction
In contrast to the normal tissue vasculature, tumor vessels are structurally and functionally
abnormal [1-3]. These abnormal tumor vessels are characterized by an irregular, disorganized,
and tortuous architecture with a highly dysfunctional and leaky endothelial cell (EC) layer [1,
3]. ECs are often loosely connected with each other and are covered by fewer and abnormal
mural pericytes (PCs) [2-4].
Research into the molecular mechanisms and physiology of PCs associated with tumor an‐
giogenesis is a critical field in cancer research. In this chapter, we will focus on the patho‐
physiology of PCs in tumor angiogenesis, the role of PCs in resistance to anti-angiogenesis
therapy, and PCs as a therapeutic target.
2. Pathophysiology of pericytes in tumor angiogenesis
Despite  the  increasing  evidence  that  PCs  plays  important  roles  in  the  angiogenic  proc‐
ess, the origin of PCs is still not fully understood. They are commonly described as orig‐
inating from various types of progenitors depending on their  anatomical location in the
body.  For example,  epicardial,  mesenchymal,  and neural  crest  cells  are believed to be a
source  for  pericytes  in  the  cardiac  coronary  vasculature,  dorsal  aorta,  and  cardiac  out‐
flow tract, respectively [5].
Pericytes play an important role in stabilizing blood vessels in the microvasculature [6, 7]. A
feature of pericyte function is their ability to provide vascular stability through crosstalk be‐
© 2013 Minami et al.; licensee InTech. This is an open access article distributed under the terms of the
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tween PCs and endothelial cells (ECs). PCs deposit matrix or releasing factors that can promote
EC differentiation or quiescence [8].
2.1. Crosstalk between ECs and PCs
In blood vessels, the crosstalk between ECs and PCs plays a critical role in the regulation of
vascular formation, maturation, remodeling, stabilization and function [9]. PCs communicate
with ECs by direct physical contact and paracrine signaling pathways.
Gap junctions provide direct contact between PCs and ECs that enable the exchange of ions
and small molecules. Adhesion plaques anchor PCs to ECs, while peg-and-socket junctions
enable the cells to penetrate the vascular basement membrane [10].
A variety of signaling factors mediate PC–EC interactions, including platelet-derived growth
factor subunit B (PDGFB) and angiopoietin/Tie 2 [11].
Figure 1. Crosstalk between endothelial cells and pericytes
2.1.1. PDGF/PDGFR family
Pericyte  homeostasis  in  normal  biology  is  regulated  in  significant  part  by  signaling
through the PDGF ligand and receptor system (Fig.  1)  [12,  13].  PDGF is  a  potent  mito‐
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gen for  pericytes  and fibroblasts.  PDGF consists  of  A,  B,  C,  and D polypeptide  chains,
and it  forms the homodimers PDGF-AA, BB,  CC,  and DD, and the heterodimer PDGF-
AB [14]. The specific tyrosine kinase receptors of the PDGFR family consist of PDGFR-α
and PDGFR-β [15, 16]. PDGFR-α binds to PDGF-AA, BB, AB, and CC, whereas PDGFR-
β binds with BB and DD [17].
Previous studies have shown that a <90% reduction in pericyte coverage in mice is compatible
with postnatal survival [18], whereas loss of >95% of pericytes is lethal [18, 19], suggesting that
a rather low threshold of pericyte density is required for basal function of microvasculature.
Activated ECs secrete PDGF-BB to attract PCs and PC progenitors, which are either tissue-
resident cells and/or cells derived from bone marrow, and express PDGFRs [20], suggesting a
paracrine signaling circuit [12, 18]. Pericyte deficiency, seen in knockout mice lacking PDGF-
BB and its receptor, PDGFR-β, resulted in various changes in microvasculature, including
endothelial hyperplasia, vessel dilation, tortuosity, leakage, and rupture, leading to wide‐
spread and lethal microhemorrhages and edema in late gestation [19, 21].
Studies of implanted tumors have shown that pericytes initially accumulate at the interface of
tumor and host tissue and later around new blood vessels, exhibiting close contacts with ECs.
Maturation of the tumor-associated vasculature is accompanied quantitatively by a reduced
PC volume and qualitatively by morphological changes in whichPCs become flattened and
elongated [22].
There is  evidence that  overexpression of  PDGF-BB in tumor cells  dramatically increases
the PC coverage [23].  Moreover, Song et al.  have also shown that tumor-derived PDGF-
BB increases tumor PC coverage by activation of stromal-derived factor 1 alpha (SDF-1α)
[24].  Thus,  PDGF-BB appears  to  be a  critical  player  in the recruitment  of  PCs to  newly
formed vessels [25].
2.1.2. Angiopoietin/Tie family
The angiopoietin (Ang) family consists of several members including Ang-1, Ang-2, Ang-3
(murine specific), and Ang-4 (human specific), which have two tyrosine kinase receptors, Tie-1
and Tie-2.
Ang-1 was initially identified as an activating ligand for Tie-2, which is expressed by perivas‐
cular cells [26]. Genetic deletion of Ang-1 resulted in prenatal lethality, due to severe heart and
vascular defects, very similar in phenotype to Tie-2-deficient mice [27]. Ang-1 is predominantly
secreted by PCs and can bind with Tie-2 on ECs in a paracrine pattern. Ang-1 enhances PC-
EC interactions, represses the proliferation and migration of ECs, and promotes the maturation
of newly formed blood vessels [27, 28]. Constitutive Ang-1/Tie-2 signaling is required to main‐
tain the quiescent vasculature [29-31] (Fig. 1).
Ang-2 was initially identified as a homologue of Ang-1 [32]. Ang-2 was found to bind to Tie-2
with an affinity similar to that of Ang-1. However, unlike Ang-1, exogenous Ang-2 produces
only a very weak activation of Tie-2 on ECs. When ECs are activated by tumor-derived pro-
angiogenic factors, Ang-2 acts as an autocrine antagonist of Ang-1/Tie-2 signaling [33]. More‐
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over, Ang-2 activates the downstream pathways including Pl3K/Akt, and thus functions as a
promoter of angiogenesis [32]. Nasarre et al. have shown that tumors implanted into geneti‐
cally Ang-2-ablated mice grew more slowly than those implanted into wild-type mice [34],
which suggests that Ang-2 is a potent target for anti-tumor therapies (Fig. 1).
Tie-2 receptor expression recently has been identified in mesenchymal cells that are present in
the stroma, implicating a repository for tumor vessel pericytes [35].
2.2. PCs in tumor angiogenesis
Many tumors express the pro-angiogenic vascular endothelial growth factor (VEGF) at high
levels [36]. In contrast to ECs in normal tissues, ECs in the tumor vasculature are dependent
on VEGF for survival [37]. Excessive VEGF signaling through VEGF receptor 2 (VEGFR2)
loosens tight junctions of ECs, increasing permeability in the interstitial tumor microenviron‐
ment. Interestingly, in tumors with reduced levels of VEGF and other angiogenic regulatory
factors, tumor vessels are less torturous, with normalized blood flow due to improved PC
coverage, the so-called ‘‘vascular normalization’’ [3, 38, 39].
PCs stabilize ECs and mediate EC survival and maturation in normal vasculature, through
both direct cell contact with ECs and paracrine signaling. It was reported that PCs in tumor
vasculature are abnormal [40]. Low PC coverage correlates with poor clinical outcome in sev‐
eral different tumor types [41-43], but so far, the active involvement of PCs in tumor progres‐
sion remains unclear. PCs are usually absent in tumor vasculature or have loose associations
with ECs, leaving most of the tumor microvessels immature, the significance of which has been
revealed in studies in which genetic or pharmacologic ablation of PC coverage facilitates
metastatic dissemination of tumor cells [43, 44].
Activated  PCs  loosely  attach  to  microvessels  and  develop  cytoplasmic  extensions  into
the tumor parenchyma [45].  Compared to quiescent PCs, activated PCs can change their
genomic expression profiles [9],  leading to phenotypes that are highly proliferative with
the  pluripotency  to  differentiate  into  other  PCs,  matrix-forming  cells,  smooth  muscle
cells, or adipocytes.
2.3. Molecular marker of PCs
The challenges of defining a PC have not been made easier by the fact that a general pan-PC
molecular marker has not been found. Because of the diverse characteristics, functions, and
locations of PCs in various organs, it probably never will be discovered. There are, however,
a few dynamic molecular markers that are present in PCs, albeit not exclusively, and that are
commonly used for their detection. The expression patterns of these markers can vary in a
tissue-specific manner or be dependent on the developmental or angiogenic stage of a blood
vessel. Desmin and alpha-smooth-muscle actin (α-SMA) are contractile filaments, and regu‐
lator of G protein signaling 5 (RGS-5) is a GTPase-activating protein; all three are intracellular
proteins. Neuron-glial 2 (NG2), a chondroitin sulfate proteoglycan, and platelet-derived
growth factor receptor beta (PDGFRβ), a tyrosine-kinase receptor, are cell-surface proteins.
Antibodies against these proteins (except RGS-5) are commonly used to identify PCs in tissue
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sections (Table 1). Desmin is a muscle-specific class III intermediate filament found in mature
skeletal, cardiac, and smooth-muscle cells.
Molecular Marker Alternative name Mouse Human
a-SMA α-Smooth muscle actin Expressed only locally by
pericytes in tumor vasculature
contractile filaments
+ +
PDGFR-β Platelet-derived growth factor
β
Tyrosine kinase receptor + +




Nestin - + +
Smooth muscle myosin - + +
Tropomyosin - + +






Expressed in pericytes in early
stages of angiogenesis
+ +
Aminopeptidase A CD249, BP1 + +




Sulphatide 3'-sulphogalactosylceramide - +
VEGFR1 vascular endothelial growth
factor receptor-1
+ +
RGS5 Regulator of G-protein
signaling-5
Novel marker for pericytes and
vascular smooth muscle cells
GTPase-activating protein
+ +
3G5 Ganglioside antigen - Specific for a pericyte surface
ganglioside
- +
Table 1. Markers of pericytes for microscopic imaging (antibody availability)
2.4. Role of bone marrow-derived PC progenitors
Bone marrow–derived hematopoietic cells expressing the PC marker NG2 were identified in
close contact with tumor blood vessels in animal models of melanoma [46], pancreatic islet
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carcinomas [47], and brain tumors [48, 49]. Thus, PC progenitor cells appear to be recruited to
sites of angiogenesis from the bone marrow niche; however, intravenously injected PC pro‐
genitor cells may fail to migrate and integrate into the tumor vasculature [50].
Tumor hypoxia due to the vascular regression following anti-angiogenic therapy appears to
induce recruitment of various bone marrow-derived cells to the tumor microenvironment [51].
Rajantie et al. demonstrated the significant contribution of bone marrow–derived cells using
an inducible hypoxia-inducible factor 1 alpha subunit (HIF1-α) animal model. In response to
hypoxia in glioblastomas [52, 53], not only Tie-2-, VEGFR1-, CD11b-, and F4/80-positive cells
but ECs and PC progenitor cells are released into the circulation from the bone marrow through
the HIF1-α signal pathway. Then, they contribute to the neovascularization of glioblastoma
[51]. In an HIF1-α knock-down mouse model, fewer bone marrow-derived cells are recruited
to the tumors, which severely impairs tumor growth. These data suggest paradoxical induction
of tumor angiogenesis via bone marrow-derived vessel progenitor cells after anti-angiogenic
therapy.
3. Role of PCs in resistance to anti-angiogenic therapies
Although an anti-VEGF therapy, bevacizumab, has shown clinical efficacy in the treatment of
several tumor types, its efficacy will ultimately be limited by acquired drug resistance. [54].
Putative mechanisms of resistance to anti-VEGF therapy include (1) activation and/or up-reg‐
ulation of alternative pro-angiogenic pathways including PDGF/PDGFR signaling in the tu‐
mor [55], (2) recruitment of bone marrow-derived pro-angiogenic cells that differentiate into
PCs, and (3) increased PC coverage of tumor microvasculature partially mediated by PDGFR
signaling [56, 57].
Studies have shown that vessels without PC coverage are more dependent on VEGF signaling
for survival [9] and that inhibition of VEGF leads to increased PC coverage of the tumor vas‐
culature [58]. PCs may protect ECs from VEGF withdrawal, leading to PC-mediated resistance
to anti-angiogenic therapies.
4. Targeting PCs as an anti-angiogenic therapy
Although a series of anti-angiogenic strategies targeting VEGF or its receptor VEGFR2 have
been shown to efficiently prevent the growth of many types of tumors [59, 60], reports have
shown that targeting VEGF signaling alone is often ineffective at inducing vascular regression
or preventing the rapid regrowth of tumor vessels [58, 61-63]. One possible explanation for
this failure is that the anti-angiogenic inhibitors mainly target immature ECs lacking PCs cov‐
erage, while showing a limited effect on the PC-associated mature vessels [63-65].
Although tumor PCs are less abundant and more loosely attached to vessels than those in
healthy tissues, they have emerged as a critical therapeutic target for anti-angiogenic therapy.
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Preclinical and clinical studies have largely focused on the role of tumor PCs in promoting EC
survival and stabilizing the tumor vasculature through a variety of signaling networks. As
noted earlier, PC recruitment to tumor neovessels is dependent on signaling through the
PDGF-BB/PDGFRβ and Ang-1/Tie-2 networks.
4.1. Targeting PDGF-BB/ PDGFRβ signaling
PDGF-BB/PDGFRβ signaling appears to be critical for maintaining the PC–EC contacts needed
for vessel stabilization. Vascular regression could also lead to the normalization of tumor mi‐
crovessels and the opening of previously collapsed vessels [66] via decreased interstitial fluid
pressure [67]. These data suggest that PDGF/PDGFR pathway inhibition is a potent target for
anti-tumor therapies by leading to improved drug delivery [68-70].
Drug Name Target Type Clinical stage
Sunitinib (Sutent) PDGFRs, VEGFRs, FLT-3,
CSF1R






Small molecule inhibitor Approved for metastatic RCC, HPCC
Pazopanib
(Votrient)
PDGFRs, VEGFRs, cKit Small molecule inhibitor Approved for metastatic RCC
Vandetanib
(Caprelsa)
PDGFRs, VEGFRs, EGFR Small molecule inhibitor Approved for metastatic medullary
thyroid cancer
Axitinib (Inlyta) PDGFRs, VEGFRs, cKit Small molecule inhibitor Approved for metastatic RCC
Motesanib PDGFRs, VEGFRs, cKit Small molecule inhibitor Phase III
Cediranib
(Recentin)
PDGFRs, VEGFRs, cKit Small molecule inhibitor Phase III
Cabozantinib PDGFRs, VEGFRs, cMet,
RET, cKit
Small molecule inhibitor Phase III
Tivozanib PDGFRs, VEGFRs, cKit Small molecule inhibitor Phase III
Regorafenib PDGFRs, VEGFRs, Raf,
cKit
Small molecule inhibitor Phase III
Table 2. PDGF/PDGFR inhibitors that are approved and/or in clinical development
Combining PDGFRβ tyrosine kinase inhibition with VEGF inhibition more efficiently blocked
tumor angiogenesis than VEGF inhibition alone in several experimental models [63, 71-74].
Bergers et al. have shown that combined treatment by anti-PDGFR agents together with anti-
VEGF significantly reduces PC coverage and increases the success of anti-tumor treatment in
the RIP1-TAG2 mouse model [63]. Similarly, PDGF inhibition disrupts PC support and sen‐
sitizes ECs to anti-angiogenic chemotherapy, resulting in regression of pre-existing tumor
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vasculature in a mouse model [13]. Long-term blockade of PDGF signaling by anti-PDGFRβ
antibody reduces the concentration of PCs within the tumor tissue and also increases the
apoptosis of ECs [73].
Several  studies  have  tested  the  effects  of  combining  anti-tumor  agents  with  anti-PC
agents  that  target  PDGF or  other  PC markers,  such as  NG2 proteoglycan [75].  Involve‐
ment  of  the  SDF-1α/CXCR4 axis  in  PC recruitment  within  PDGF-BB–overexpressing tu‐
mors  suggests  that  a  blockade  of  this  axis  may  provide  an  additional  target  in  anti-
angiogenic tumor therapy [24].
Most recently, treatment of primary tumors in an animal model of breast cancer with combi‐
nation VEGF and PDGF receptor therapy led to decreased PC coverage and an increased
number of metastases. The observed promotion of metastasis by imatinib is consistent with
previous reports demonstrating the key role of PDGFRβ signaling in PC recruitment and the
importance of PCs in limiting tumor cell metastasis [43]. These findings provide the mecha‐
nistic basis for the differential effects these agents have on metastasis promotion.
However, a human clinical trial for renal carcinoma showed that inhibition of both the VEGF
and PDGF pathways resulted in no therapeutic benefit when compared to inhibition of the
VEGF pathway alone; in fact, the combined regimen exhibited toxicity [76]. Given these results,
further preclinical studies are needed to clarify the mechanism(s) by which PDGF-targeted
agents affect PC–EC interactions, and additional clinical studies are needed to clarify the po‐
tential benefits and risks associated with anti-PC tumor therapy.
4.2. Targeting Ang/Tie signaling
PCs have been shown to stabilize blood vessels and provide EC survival signals through the
Ang-1/Tie-2 pathway [73, 77]. Therefore, by targeting tumor PCs it may be possible to over‐
come PC-mediated resistance to VEGF pathway inhibition and achieve more effective tumor
vessel destabilization through disruption of the PC–EC association or directly through PC loss.
Trebananib (AMG 386) is a peptide-Fc fusion protein that inhibits angiogenesis by neutralizing
the interaction between the Tie-2 receptor and Ang-1 and Ang-2 [78]. In phase I testing, it was
found to be well tolerated in combination with chemotherapy [79] and to reduce tumor blood
flow or permeability [80]. In a phase II trial of trebananib in combination with paclitaxel in
patients with recurrent ovarian cancer, although a statistically significant improvement in
progression-free survival for the treatment arm was not observed, the objective response rates
and progression-free survival at the higher dose are suggestive of an antitumor effect [81]. The
toxicity profile, including peripheral edema but not bowel perforations, is consistent with a
mechanism distinct from that of VEGF inhibitors. Trebananib plus paclitaxel is now being
investigated in an ongoing phase III study (TRINOVA-1 [Trial in Ovarian Cancer-1]) for the
treatment of recurrent ovarian cancer. Phase II trials in breast, colorectal, kidney, stomach, and
liver cancers are underway.
CVX060 (PF-04856884) is a recombinant humanized monoclonal antibody fused to two Ang-2
binding peptides [82, 83]. In preclinical studies, CVX-060 was anti-angiogenic and decreased
tumor proliferation. In phase I testing, this agent significantly decreased tumor blood flow and
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affected circulating serum Ang-2 levels. This agent is being evaluated in combination with
sunitinib in renal cell carcinoma. Currently, a phase II trial for kidney and a phase I trial for
other solid tumors are underway.
Other agents in development include monoclonal antibodies directed against Ang-2
(MEDI-3617, AMG 780, REGN910) and multi-targeted tyrosine kinase inhibitors inhibiting
Tie-2 (CEP11981, ARRY614) [84].
4.3. Other approaches
At least two alternative therapeutic approaches appear plausible given the role of PCs in
promoting  tumor  angiogenesis.  The  first  approach  is  to  promote  excessive  PC  recruit‐
ment, thereby causing vessel stabilization and restricting vessel sprouting. This approach
may  limit  tumor  angiogenesis  in  blood  vessels  with  normal  PC  investment  of  the  EC
and may prevent  the  dissemination  of  tumor  cells  into  the  circulation  by  reducing  the
leakiness  of  intratumoral  blood  vessels  and,  perhaps,  by  also  blocking  extravasation  of
circulating tumor cells.
The second approach involves the use of PC progenitor cells as a cellular vehicle for gene
delivery. This idea is supported by previous work using progenitor ECs [85-87], and more
recently, PCs [50] to deliver anti-angiogenic gene therapy.
Neither of these approaches promoting PC recruitment to the tumor vasculature has been
tested in preclinical models or clinical trials; both are highly speculative and no proof-of-prin‐
ciple studies have been conducted in animal models.
5. Conclusions
Based on the crucial role of PCs in microvessel maturity and the concomitant histological
evaluation of EC-PC interactions and tumor microvessel morphology, combining different
chemotherapeutic agents and anti-angiogenic treatments that normalize tumor vasculature
seems to be inevitable. Many new angiogenic inhibitors target pathways that are involved in
the recruitment of PCs to tumor microvessels. Therefore, it is essential to assess PCs in parallel
with ECs when studying tumor vasculature. This evaluation, which can be performed in a
diagnostic pathology laboratory, can be used as a decision-making tool to select patients who
might benefit from anti-angiogenic therapies.
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